 Indoles
"Indoles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Benzopyrroles with the nitrogen at the number one carbon adjacent to the benzyl portion, in contrast to ISOINDOLES which have the nitrogen away from the six-membered ring.
| Descriptor ID |
D007211
|
| MeSH Number(s) |
D03.633.100.473
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Indoles".
Below are MeSH descriptors whose meaning is more specific than "Indoles".
This graph shows the total number of publications written about "Indoles" by people in this website by year, and whether "Indoles" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1991 | 1 | 0 | 1 | | 1992 | 2 | 0 | 2 | | 1994 | 1 | 1 | 2 | | 1996 | 2 | 2 | 4 | | 1997 | 1 | 5 | 6 | | 1998 | 0 | 1 | 1 | | 1999 | 1 | 4 | 5 | | 2000 | 1 | 5 | 6 | | 2001 | 3 | 4 | 7 | | 2002 | 2 | 3 | 5 | | 2003 | 1 | 6 | 7 | | 2004 | 1 | 5 | 6 | | 2005 | 3 | 2 | 5 | | 2006 | 3 | 3 | 6 | | 2007 | 4 | 6 | 10 | | 2008 | 5 | 6 | 11 | | 2009 | 3 | 7 | 10 | | 2010 | 3 | 1 | 4 | | 2011 | 2 | 7 | 9 | | 2012 | 5 | 8 | 13 | | 2013 | 6 | 8 | 14 | | 2014 | 11 | 9 | 20 | | 2015 | 10 | 9 | 19 | | 2016 | 5 | 1 | 6 | | 2017 | 7 | 5 | 12 | | 2018 | 6 | 2 | 8 | | 2019 | 7 | 7 | 14 | | 2020 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Indoles" by people in Profiles.
-
Pasupneti S, Tian W, Tu AB, Dahms P, Granucci E, Gandjeva A, Xiang M, Butcher EC, Semenza GL, Tuder RM, Jiang X, Nicolls MR. Endothelial HIF-2a as a Key Endogenous Mediator Preventing Emphysema. Am J Respir Crit Care Med. 2020 10 01; 202(7):983-995.
-
Wells AU, Flaherty KR, Brown KK, Inoue Y, Devaraj A, Richeldi L, Moua T, Crestani B, Wuyts WA, Stowasser S, Quaresma M, Goeldner RG, Schlenker-Herceg R, Kolb M. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respir Med. 2020 05; 8(5):453-460.
-
Le Cras TD, Abman SH. Early Disruption of VEGF Receptor Signaling and the Risk for Adult Emphysema. Am J Respir Crit Care Med. 2020 03 01; 201(5):620-621.
-
Flaherty KR, Wells AU, Brown KK. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. Reply. N Engl J Med. 2020 02 20; 382(8):781.
-
García-Arroyo FE, Muñoz-Jiménez I, Gonzaga G, Tapia E, Osorio-Alonso H, Roncal-Jiménez CA, Iroz A, Vecchio M, Reyes-García JG, Johnson RJ, Sánchez-Lozada LG. A Role for Both V1a and V2 Receptors in Renal Heat Stress Injury Amplified by Rehydration with Fructose. Int J Mol Sci. 2019 Nov 16; 20(22).
-
Heijerman HGM, McKone EF, Downey DG, Van Braeckel E, Rowe SM, Tullis E, Mall MA, Welter JJ, Ramsey BW, McKee CM, Marigowda G, Moskowitz SM, Waltz D, Sosnay PR, Simard C, Ahluwalia N, Xuan F, Zhang Y, Taylor-Cousar JL, McCoy KS. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet. 2019 11 23; 394(10212):1940-1948.
-
Zemanick ET, Accurso FJ. Entering the era of highly effective CFTR modulator therapy. Lancet. 2019 11 23; 394(10212):1886-1888.
-
Middleton PG, Mall MA, Drevínek P, Lands LC, McKone EF, Polineni D, Ramsey BW, Taylor-Cousar JL, Tullis E, Vermeulen F, Marigowda G, McKee CM, Moskowitz SM, Nair N, Savage J, Simard C, Tian S, Waltz D, Xuan F, Rowe SM, Jain R. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. N Engl J Med. 2019 11 07; 381(19):1809-1819.
-
Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, Richeldi L, Kolb M, Tetzlaff K, Stowasser S, Coeck C, Clerisme-Beaty E, Rosenstock B, Quaresma M, Haeufel T, Goeldner RG, Schlenker-Herceg R, Brown KK. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N Engl J Med. 2019 10 31; 381(18):1718-1727.
-
Wollin L, Distler JHW, Redente EF, Riches DWH, Stowasser S, Schlenker-Herceg R, Maher TM, Kolb M. Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases. Eur Respir J. 2019 09; 54(3).
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|